By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
Bristol-Myers Squibb (BMY) And Nektar Therapeutics (NKTR) Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo(Nivolumab) And NKTR-214 9/27/2016 11:07:34 AM
Nektar Therapeutics (NKTR) To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb (BMY) 9/27/2016 10:06:30 AM
Drug Giant Bristol-Myers Squibb (BMY) Ties it Up With Another Bay Area Firm in Cancer Immunotherapy Quest 9/27/2016 5:41:17 AM
Bristol-Myers Squibb (BMY) To Take Part In Leerink Partners Immuno-Oncology Roundtable Conference 9/22/2016 11:13:22 AM
EMA Validates Bristol-Myers Squibb (BMY)’s Type II Variation Application For Opdivo (nivolumab) In Advanced Form Of Bladder Cancer 9/20/2016 11:47:26 AM
Bristol-Myers Squibb (BMY) Awards First "Golden Tickets" For LabCentral To PanTher, Suono Bio 9/20/2016 11:21:21 AM
Bristol-Myers Squibb (BMY) Employees Cycle Coast To Coast To Raise Money And Awareness For Cancer Research 9/7/2016 2:10:50 PM
Bristol-Myers Squibb (BMY) To Present At Bank of America (BAC) And Merrill Lynch Global Health Care Conference 9/7/2016 10:40:03 AM
Bristol-Myers Squibb (BMY) To Announce Results For Third Quarter 2016 On October 27 9/7/2016 10:37:28 AM
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s ORENCIA (Abatacept) For The Treatment Of Highly Active And Progressive Disease In Adult Patients With Rheumatoid Arthritis Not Previously Treated With Methotrexate 9/6/2016 11:40:36 AM
12345678910...
//-->